Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its lead product candidate is Xtampza, an oral formulation of oxycodone. The company is also developing COL-195, a hydrocodone for the treatment of chronic pain; COL-172, an oxymorphone for the treatment of chronic pain; COL-196, a morphine formulation to treat pain; and COL-171, a proprietary preclinical DETERx methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.
http://www.priceseries.com/trade/COLL-Collegium-Pharmaceutical-Inc-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2017110920171127.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments